Bayer AG's long-acting treatment for hemophilia A has won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily.
from Reuters: Health News https://ift.tt/2QOz2ej
No comments:
Post a Comment